Market Currents
GSK's (GSK) once-daily lung drug LAMA/LABA performed well in late-stage testing in patients with...
-
Monday, July 2, 2012, 8:18 AM ETGSK's (GSK) once-daily lung drug LAMA/LABA performed well in late-stage testing in patients with chronic obstructive pulmonary disease. GSK, which plans to begin filing for regulatory approval at the end of the year, hopes LAMA/LABA will be a successor to Advair. GSK is developing the drug with Theravance (THRX), whose shares are +8%.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
